All In Biotech

Drug Trial Radar · NCT06411314

Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis

Efficacy and Safety of Vaginal Suppositories Containing Combination of Natamycin and Lactulose in Treatment of Vulvovaginal Candidiasis: International, Randomized, Controlled, Superiority Clinical Trial

Last checked: Nov 19, 2026Latest source record: May 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

218

Actual

Start

Dec 29, 2022

Primary completion

Jul 26, 2023

Study completion Sep 22, 2023

Sponsor

Lead sponsor
Avva Rus, JSCIndustry
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose is to study superior efficacy of combination of Natamycin and Lactulose (Natamycin 100 mg + Lactulose 300 mg vaginal suppositories) compared to Pimafucin (Natamycin 100 mg vaginal suppositories), or Lactulose 300 mg vaginal suppositories. The second objective of the study was to investigate the safety of the combination suppositories in the treatment of vulvovaginal candidiasis in non-pregnant adult females.

Conditions

  • Vulvovaginal Candidiasis, Genital

Interventions

  • Natamycin + Lactulose 100 mg + 300 mg vaginal suppositoriesCombination product

    1 suppository once daily at bedtime for 6 days

  • Lactulose 300 mg vaginal suppositoriesDrug

    1 suppository once daily at bedtime for 6 days

  • Pimafucin® (natamycin) 100 mg vaginal suppositoriesDrug

    1 suppository once daily at bedtime for 6 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion (%) of patients who achieved a clinical response (recovery) at Visit 2Time frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Reproductive Medicine and Surgery at the A.I. Evdokimov Moscow State Medical and Dental University

    Moscow, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.